Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ENVISION: A Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Study With an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients With Acute Hepatic Porphyrias

NCT03338816 is registered in ClinicalTrials.gov with Alnylam Pharmaceuticals as lead sponsor.

NCT NCT03338816
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03338816 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ENVISION: A Phase 3 Randomized, Double-blind, Placebo-Controlled Multicenter Study With an Open-label Extension to Evaluate the Efficacy and Safety of Givosiran in Patients With Acute Hepatic Porphyrias
Lead sponsor
Alnylam Pharmaceuticals
Phase
Phase 3
Overall status
Completed
Start date
November 16, 2017
Completion date
May 31, 2021
Enrollment
94 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

acute hepatic porphyria, acute intermittent porphyria, acute porphyria, ala dehydratase deficient porphyria (adp), hereditary coproporphyria (hcp), porphyria, acute intermittent, variegate porphyria (vp)